Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.03.2024 | Case report

Entrectinib

Grade 3 transaminitis and grade 1 dysgeusia

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Narvel HG, et al. Orthogonal Testing Unravels a Novel ROS1 Oncogenic Fusion Variant (ROS1-GPM6A): A Practical Approach to Molecular Testing for Actionable Fusion Variants. JCO Precision Oncology 7 : 1-8, Jan 2023. Available from: URL: 10.1200/PO.22.00593 Narvel HG, et al. Orthogonal Testing Unravels a Novel ROS1 Oncogenic Fusion Variant (ROS1-GPM6A): A Practical Approach to Molecular Testing for Actionable Fusion Variants. JCO Precision Oncology 7 : 1-8, Jan 2023. Available from: URL: 10.1200/PO.22.00593
Metadaten
Titel
Entrectinib
Grade 3 transaminitis and grade 1 dysgeusia
Publikationsdatum
01.03.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-54062-8

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Sorafenib

Case report

Pembrolizumab

Case report

Multiple drugs